| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc68208fb5d61430ee394c3d87c8af67 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-79 |
| filingDate |
2020-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd88898bc664c69cd139ec87172c5f4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d355a93bb14cae42fed185dda0c4970d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6ef23e076c2eb9054f0f65d20f190ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_beef05b4e0e3a3fe64b9104fc03f6998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9969d148355f7c6f6b6e5d5ee25828d |
| publicationDate |
2021-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2747904-C1 |
| titleOfInvention |
Method for treatment of patients with ulcerative collitis using alfazox |
| abstract |
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery and gastroenterology, and for the treatment of patients with ulcerative colitis. For this, in addition to the first-line drugs - mesalazine 1-2 g / day in the form of suppositories and budesonide 2 mg / day in the form of rectal foam, the drug Alfazox is administered. 1 sachet containing 10 ml of Alfazox is mixed with 15 ml of 0.9% sterile NaCl solution. The prepared suspension is administered rectally by microclysters, twice a day for 14 days.EFFECT: method provides for increased efficiency and decreased duration of treatment due to the protective effect of the complex of drugs on the mucous membrane, which helps to reduce inflammation and the healing of ulcerative and erosive defects.1 cl; 2 ex |
| priorityDate |
2020-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |